Molecular structure of Dolasetron mesylate, CAS Number: 115956-13-3
Dolasetron mesylate (CAS 115956-13-3)
Alternate Names:
Anzemet
CAS Number:
115956-13-3
Molecular Weight:
420.48
Molecular Formula:
C20H24N2O6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Dolasetron mesylate is a serotonin 5-HT3 receptor antagonist that functions by selectively blocking the action of serotonin at 5-HT3 receptors. Dolasetron mesylate′s mechanism of action involves binding to the receptor and inhibiting the signal transduction pathway. Dolasetron mesylate competes with serotonin for binding to the 5-HT3 receptor, leading to the inhibition of serotonin-induced ion currents. Dolasetron mesylate′s function in the experiments involves its ability to target and block the 5-HT3 receptor, thereby modulating the physiological response to serotonin. By disrupting the receptor-ligand interaction, dolasetron mesylate effectively interferes with the transmission of emetic signals, demonstrating its role as a potent and selective antagonist of the serotonin 5-HT3 receptor.
Dolasetron mesylate (CAS 115956-13-3) References
- Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. | Coppes, MJ., et al. 1999. J Pediatr Hematol Oncol. 21: 274-83. PMID: 10445889
- Single- and Multiple-Dose Pharmacokinetics of Reduced Metabolite (MDL 74,156) following Oral Administration of Dolasetron Mesylate to Normal Male Subjects. | Shah, A., et al. 1996. Am J Ther. 3: 364-370. PMID: 11862273
- Stability of dolasetron in two oral liquid vehicles. | Johnson, CE., et al. 2003. Am J Health Syst Pharm. 60: 2242-4. PMID: 14619116
- Dolasetron overdose resulting in prolonged QTc interval and severe hypotension: a case report and literature review. | Rochford, M., et al. 2007. Emerg Med J. 24: 515-7. PMID: 17582056
- Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients. | Kim, JS., et al. 2004. Cancer Res Treat. 36: 372-6. PMID: 20368831
- CdS nanocrystals as fluorescent probe for detection of dolasetron mesylate in aqueous solution: Application to biomedical analysis. | Pawar, SP., et al. 2016. J Pharm Anal. 6: 410-416. PMID: 29404011
- Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study. | He, G., et al. 2017. Eur J Hosp Pharm. 24: 162-166. PMID: 31156929
- Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. | Conroy, T., et al. 1994. Am J Clin Oncol. 17: 97-102. PMID: 8141114
- Determination of dolasetron and its reduced metabolite in human plasma by GC-MS and LC. | Gillespie, TA., et al. 1993. J Pharm Biomed Anal. 11: 955-62. PMID: 8305600
- Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. | Dempsey, E., et al. 1996. J Clin Pharmacol. 36: 903-10. PMID: 8930777
- Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children. | Lerman, J., et al. 1996. Clin Pharmacol Ther. 60: 485-92. PMID: 8941021
- Validation of a reversed-phase HPLC method for directly quantifying the enantiomers of MDL 74,156, the primary metabolite of dolasetron mesylate, in human plasma. | McElvain, JS., et al. 1997. J Pharm Biomed Anal. 15: 513-21. PMID: 8953495
- Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction. | Stubbs, K., et al. 1997. J Clin Pharmacol. 37: 926-36. PMID: 9505984
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dolasetron mesylate, 100 mg | sc-279005 | 100 mg | $103.00 |